Frontiers in Clinical Drug Research-Diabetes and Obesity
Shazia Anjum, B0BZWPM7JL, 9815123599, 9815123602, 9789815123609, 978-9815123609, 978-9815123609, 978-981-5123-58-6, 978-9815123586, 9789815123586, 978-981-5123-59-3, 978-9815123593, 9789815123593
Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The sixth volume of this series features 6 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist. - The failing heart in diabetes with special emphasis on prevention- Flavonoids as prominent anti-diabetic agents- Chemosensor in glucose monitoring, advances and challenges - Synergistic drugs and polyherbal formulations for obesity: current status and future prospectives- Urge for herbal anti-diabetic medicines towards clinical and therapeutic implications- Curcuma longa as a dietary supplement and medication for diabetes mellitus: evidence from experimental studies.